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0.16). Presence of ADA was found in 16 patients, correlated with the development of infusion reactions
(OR: 10.6, RR: 5.4, CI: 2.9–38.6), and was associated with subtherapeutic TL in 15 patients (93.8%).
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Abstract
Background and Aims: The majority of patients treated with 
anti-tumor necrosis factor (TNF) therapy develop anti-drug 
antibodies (ADAs), which might result in loss of treatment 
efficacy. Strict guidelines on measuring trough levels (TLs) 
and ADA in clinical routine do not exist. To provide real-
world data, we took advantage of our tertiary inflammatory 
bowel disease (IBD) center patient cohort and determined 
indicators for therapeutic drug monitoring (TDM) and actual 
consequences in patient care. Methods: We retrospectively 
collected clinical data of 104 IBD patients treated with inflix-
imab or adalimumab in our IBD clinic. Patients with TL and 
ADA measurements between June 2015 and February 2018 
were included. Results: The main reason for determining TL 
was increased clinical disease. Subtherapeutic TLs were 
found in 33 patients, therapeutic TLs in 33 patients, and su-
pratherapeutic TLs in 38 patients. Adjustments in anti-TNF 
therapy occurred more frequently (p = 0.01) in patients with 
subtherapeutic TL (24 of 33 patients; 73%) as compared to 
patients with therapeutic and supratherapeutic TLs (26 of 71 
patients; 37%). No correlation could be found between TL 
and disease activity (p = 0.16). Presence of ADA was found in 
16 patients, correlated with the development of infusion re-
actions (OR: 10.6, RR: 5.4, CI: 2.9–38.6), and was associated 
with subtherapeutic TL in 15 patients (93.8%). Treatment ad-
aptations were based on TL and/or ADA presence in 36 of 63 
patients. Conclusions: TDM showed significant treatment 
adaptations in patients with subtherapeutic TL. Conversely, 
in patients with therapeutic and supratherapeutic TLs, rea-
sons for adaptations were based on considerations other 
than TL, such as clinical disease activity. Further studies 
should focus on decision-making in patients presenting 
with supratherapeutic TL in remission.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Anti-tumor necrosis factor (TNF) antibodies, such as 
infliximab and adalimumab, are important medications 
for the treatment of patients with inflammatory bowel 
disease (IBD). However, biological agents (biologicals) 
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-
mercial purposes requires written permission.
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are costly, thus burdening the health care system [1]. The 
development of sustained anti-drug antibodies (ADAs) 
occurs in up to 73% of patients treated with infliximab 
and up to 35% of patients treated with adalimumab [2]. 
The presence of ADA commonly results in a loss of re-
sponse, which usually occurs within 12 months after the 
onset of treatment in about one-third of patients [2]. 
Moreover, ADA can cause other adverse events, such as 
infusion reactions [3, 4]. Therefore, the measurement of 
anti-TNF antibody trough levels (TL) and the determi-
nation of ADA are frequently performed to optimize the 
management of patients with IBD [5–7]. Therapeutic 
drug monitoring (TDM) can be done to either detect a 
possible reason for treatment failure or loss of response 
(so-called “reactive” TDM), or to optimize therapy out-
come and prevent flares or loss of response (so-called 
“proactive” TDM) [2].
Although the European Crohn’s and Colitis Organi-
zation (ECCO) states the existence of a positive dose-
response relationship between TL and clinical outcomes, 
the ECCO does not provide a detailed recommendation 
on when to measure TL or ADA in the clinical routine 
setting [8]. However, recent consensus panels proposed 
to determine TL and ADA after successful induction and 
when treatment failure occurs [2, 9]. In addition, mea-
surement of ADA is recommended before reinitiating 
anti-TNF therapy to avoid an acute infusion reaction 
[10]. The development of ADA can be reduced by con-
comitant treatment with immunomodulators (i.e., thio-
purines or methotrexate [MTX]) [11]. Alternatively, 
ADA levels may increase or even disappear spontane-
ously over time without any clinical relevance [12]. Re-
garding TL of infliximab or adalimumab, it is recom-
mended to maintain high levels because these were found 
to be beneficial for endoscopic remission in luminal IBD 
[2, 11, 13, 14]. However, no official recommendation ex-
ists about the optimal range of TL to maintain clinical 
remission. In addition, the consequences of TL measure-
ments, including dosing or time interval adaptation of 
the biological, change of the biological, and addition or 
alterations of immunomodulatory treatments, have only 
been described in a few studies [15–17].
Thus, due to a lack of common guidelines, it is un-
clear at present, in which clinical settings TL and ADA 
should be measured and which consecutive treatment 
adaptations are warranted. Therefore, we aimed to ana-
lyze the reasons for and consequences of TL and ADA 
measurements in the clinical real-life setting in our 




We retrospectively analyzed the charts of 104 IBD patients 
who had measurements of TL and ADA when attending our ter-
tiary care IBD center at the University Hospital Zurich (USZ), 
Switzerland, between June 2015 and February 2018. All enrolled 
patients were participants of the Swiss IBD Cohort study, which 
was approved by the Ethics Committee of the Canton Zurich 
(No. EK-1316). Every patient was treated with infliximab or 
adalimumab. Patient characteristics and additional IBD-related 
treatments were extracted from the electronic health record sys-
tem of the USZ. Disease classification at the time of serum anal-
ysis was documented by the Montreal classification, including 
disease severity by either the Harvey-Bradshaw Index (HBI) for 
Crohn’s disease (CD) or the Modified Truelove and Witts Sever-
ity Index score (MTWSI) for ulcerative colitis (UC) [18, 19]. 
Only one measurement per patient was taken for analysis in this 
study, namely the first measurement that was performed within 
the time period of data analysis. Further measurements of TL in 
the patients were analyzed but not included in the initial analysis 
due to the diversity and disparity of patients’ follow-up.
The detailed reasons for performing TL and ADA measure-
ments were subdivided into 10 different groups based on the 
notes of the treating physician: (1) clinical flare, (2) sonographic 
activity, (3) endoscopic activity, (4) elevated laboratory param-
eters (C-reactive protein and fecal calprotectin), (5) TL monitor-
ing without any ongoing adaptation of dosing (quiescent dis-
ease), (6) TL monitoring during ongoing adaptation of dosing, 
(7) TL monitoring at the end of treatment induction, (8) recent 
presence of ADA, (9) suspected side effect of anti-TNF therapy 
or suspected presence of ADA, and (10) verification of potential 
ADA development due to former exposure to the same biological 
prior to reinitiation. TL results for infliximab and adalimumab 
were classified into 3 subgroups specified as “subtherapeutic” 
(infliximab <3.5 μg/L and adalimumab <5 μg/L), “therapeutic” 
(infliximab 3.5–7 μg/L and adalimumab 5–8 μg/L), and “supra-
therapeutic” (infliximab >7 μg/L and adalimumab >8 μg/L), 
based on the publication of Vande Casteele and colleagues [20].
The performed treatment adaptations following the results of 
TL and ADA measurements were subdivided into the following 
3 groups: (1) adaptation of anti-TNF therapy (dose or interval 
change, stopping ongoing anti-TNF therapy, or change to an-
other biological treatment, such as infliximab, adalimumab, go-
limumab, and vedolizumab), (2) treatment changes other than 
anti-TNF therapy (initiation of immunomodulators, e.g., aza-
thioprine [AZA] or MTX; corticosteroids [topical or systemic]; 
surgery; or antibiotics), and (3) no treatment adaptation. One 
patient could belong to groups (1) and (2) if both anti-TNF ther-
apy adaptation and addition of immunomodulators were ap-
plied.
Physicians’ notes available from the electronic health record 
system were analyzed to define if performed treatment adapta-
tions were based on the results from TL and ADA measurements 
or if these decisions were established based on clinical signs and 
other investigations, such as laboratory results or sonographic or 
endoscopic appearance, regardless of TL and ADA results. If fol-
low-up measurements were performed, the interval between TL 
measurements, development of ADA, and therapeutic conse-
quences in case of ADA development were recorded.
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Table 1. Clinical and demographic patient characteristics at first trough level measurements
UC (n = 30) CD (n = 74) p  
value
count % mean range count % mean range
Sex
Female 14 47 39 53
Male 16 57 35 47
Age at measurement, years 38 (17–74) 35 (12–70) 0.49
Age at diagnosis, years 30 (12–68) 25 (6–63) 0.22
Smoker
No 26 87 49 67 0.03
Yes 4 13 24 33
Extraintestinal manifestations (joint, skin, and ocular)
No 15 50 45 62 0.19
Yes 15 50 28 39
Surgery
No 27 90 32 44 <0.01
Yes 3 10 41 56
Anti-TNF therapy
Infliximab 22 73 42 57 0.09
Adalimumab 8 27 32 43
Infliximab dosage, mg/kg 5 (5–10) 6 (5–10)
Infliximab treatment interval, days 47 (28–56) 49 (14–56)
Adalimumab dosage, mg 40 (40) 43 (40–80)
Adalimumab treatment interval, days 12 (7–14) 14 (7–21)
Immunomodulators or other concomitant treatments
None of the mentioned treatments 1 3 41 55
AZA 3 10 7 10
MPU 1 3 1 1
Corticosteroids, syst 3 10 6 8
Methotrexate 1 3 2 3
Corticosteroids, topical 0 3 4
Antibiotics 0 3 4
5-ASA 8 27 2 3
Corticosteroids syst and antibiotics 0 2 3
Corticosteroids syst and AZA or MPU 4 13 2 3
Corticosteroids syst and MTX 1 3 2 3
Corticosteroids syst and 5-ASA 6 20 1 1
Others1 2 7 2 3
MTWSI at presentation 7 (1–16)
Montreal classification UC (E1–E3)
E1: Proctitis 4 13
E2: Left-sided colitis 13 43
E3: Pancolitis 13 43
HBI at presentation 6 (1–14)
Montreal classification CD: location (L1–L4)
L1 (ileal) 14 19
L2 (colonic) 22 30
L3 (ileocolonic) 35 47
L4 (isolated upper disease) 3 4
Montreal classification CD: behavior (B1–B3)
B1 (nonstricturing, nonpenetrating) 27 36
B2 (stricturing) 7 9
B3 (penetrating) 40 54
CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumor necrosis factor; AZA, azathioprine; MPU, mercaptopu-
rine; syst, systemic; 5-ASA, 5-aminosalicylic acid; MTX, methotrexate; MTWSI, Modified Truelove and Witts Se-
verity Index score; HBI, Harvey-Bradshaw Index. 1 Others: tacrolimus, vedolizumab, study drug, or cyclosporine.
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Detection of Infliximab and Adalimumab TLs and ADAs
Serum for TL and ADA analysis was obtained immediately 
before the next infliximab or adalimumab application or on the 
day of admission for hospitalized patients. TL and ADA levels for 
infliximab were measured using a commercially available ELISA 
kit (Lisa Tracker Duo Infliximab, Theradiag, France), which is a 
drug-sensitive assay. The normal range for infliximab TL was set 
to 3.5–7 μg/L, consistent with a previous publication [14]. ADAs 
against infliximab were categorized into present or negative (<10 
ng/mL). TL and ADA levels for adalimumab were analyzed using 
a commercially available ELISA kit (Lisa Tracker Duo Adali-
mumab, Theradiag, France), a drug-sensitive assay. The normal 
range for adalimumab TL was determined to be 5–8 μg/L [14]. 
ADAs against adalimumab were categorized into present or neg-
ative (<10 ng/mL). Due to similar assay characteristics, TL and 
ADA measurements were always performed in parallel. All anal-
yses were routinely performed by the Department of Immunol-
ogy at the University Hospital Zurich.
Data Analysis and Statistics
Data were analyzed using SPSS version 25.0 (IBM Corp., Ar-
monk, NY, USA). p < 0.05 was considered statistically significant. 
Patients’ baseline characteristics in Table  1 were analyzed by 
Mann-Whitney U test and χ2 test for continuous and categorical 
data, respectively.
For analysis of the performed treatment adaptations, we used 
χ2 test and the exact binomial test, including the analysis of the 3 
possible TL results (sub-, supra-, or therapeutic), and subse-
quently performed changes in anti-TNF therapy: (1) yes, mean-
ing adaptation performed by higher dosing, interval shortening 
or lengthening, stopping or switching of biological treatment; 
(2) no, meaning no treatment adaptation regarding anti-TNF 
therapy; analysis of correlation between clinical surrogate for in-
creased disease activity (clinical flare, a sonographic or endo-
scopic activity, or elevated laboratory parameters) and the 3 pos-
sible TL results; analysis regarding physicians’ motivation for 
consequent treatment adaptations compared to the 3 TL results. 
Odds ratios were calculated for the presence of ADA and adverse 




Demographic details and patient characteristics are 
presented in Table 1. A total of 104 patients (CD: n = 74; 
UC: n = 30) were included. The majority was regularly 
seen in an ambulatory outpatient setting (n = 87) in the 
context of a specialized tertiary IBD clinic. A subset of 
patients (n = 17) was hospitalized due to disease flares 
needing intravenous antibiotics or corticosteroids. One 
of those patients was hospitalized in the intensive care 
unit due to a septic shock. Three patients received both 
infliximab and adalimumab in succession if one of the 
drugs lost effectiveness. The frequency of treatment 
with either infliximab or adalimumab in CD or UC was 
not different (p = 0.08). The dosage of infliximab ranged 
from 5 to 10 mg/kg body weight and was administered 
in intervals of 4–8 weeks. Adalimumab was mostly given 
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Fig. 1. Reasons for TL measurements (n = 
104, CD and UC patients): clinical flare (a) 
(i.e., symptoms or signs for disease activity) 
was the main reason for measurement of 
TL, followed by TL monitoring without 
treatment adaptation (b) (quiescent dis-
ease and proactive monitoring). Suspected 
side effect of anti-TNF therapy or suspect-
ed presence of ADAs (c); elevated labora-
tory parameters (C-reactive protein and fe-
cal calprotectin) (d); sonographic activity 
(e); endoscopic activity (f); TL monitoring 
at the end of treatment induction (g); veri-
fication of potential ADA development 
due to former exposure to the same bio-
logical before reinitiation (h); recent pres-
ence of ADA (i); TL monitoring with ongo-
ing adaptation of dosing (j). TL, trough 
level; CD, Crohn’s disease; UC, ulcerative 
colitis; TNF, tumor necrosis factor; ADAs, 
anti-drug antibodies.
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Reasons for TL Measurements
The detailed reasons for TL measurements are repre-
sented in Figure 1. TL measurements were mainly per-
formed in patients presenting with a clinical flare (38 pa-
tients, 36.5%), such as higher frequency of diarrhea, 
bloody stools, abdominal cramps, or painful abdominal 
palpation indicative for increased disease activity. Inter-
estingly, proactive TDM was the second leading reason 
for TL measurements (15 patients, 14.4%), while other 
signs of enhanced disease activity, such as elevated CRP 
or calprotectin levels, sonographic or endoscopic disease 
activity, or suspected side effects, were less often the rea-
son for TL determination.
TL Results and Subsequent Treatment Adaptations
An overview of TLs and their impact on treatment de-
cisions are given in Figure 2. One patient could undergo 
both a change in anti-TNF therapy and other treatment 
adaptations, such as change or addition of immunomod-
ulators and corticosteroids.
Subtherapeutic TLs were found in 33 patients. Out of 
the 22 patients with anti-TNF therapy changes, 9 (41%) 
received a treatment intensification (i.e., higher dosing, 
reinduction of therapy, or interval shortening). Seven-
teen out of 33 patients (52%) with subtherapeutic TL had 
(additionally) other treatment adaptations not involving 
anti-TNF therapy, such as introduction of immunomod-
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Subtherapeutic: IFX: <3.5 μg/L; ADM: <5 μg/L
Therapeutic: IFX: 3.5-7 μg/L; ADM: 5–8 μg/L
Supratherapeutic: IFX: >7 μg/L; ADM: >8 μg/L
Fig. 2. Results of TL measurements and resulting therapeutic consequences: treatment adaptations (regarding 
anti-TNF therapy and other adaptations) were mainly performed in patients presenting with subtherapeutic TLs. 
One patient could have received both changes in anti-TNF therapy and other treatment adaptations. TL, trough 
level; TNF, tumor necrosis factor.
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Therapeutic TLs were found in 33 patients and fre-
quently resulted in no treatment adaptations at all. How-
ever, in patients presenting with a clinical flare, anti-TNF 
therapy was intensified together with initiation of topical 
(n = 4) or systemic (n = 4) corticosteroids.
Supratherapeutic TLs were found in 38 patients. Inter-
estingly, these were followed by intensification of therapy 
in 10 (26%) patients (reasons for this will be explained in 
detail below). Treatment was left unchanged in the ma-
jority of patients (52%).
By performing a crosstable analysis, we could demon-
strate a significant correlation between the 3 TL groups 
and the resulting adaptations of anti-TNF therapy (Pear-
son’s χ2 = 12.03, p < 0.01). Analyzing the 3 TL groups in-
dependently, significant adaptations of anti-TNF therapy 
were only evident in the subtherapeutic TL group (exact 
binomial test, 2-sided, p = 0.01), but not in the other 2 
groups (Table 2). Other treatment adaptations (i.e., not 
involving anti-TNF therapy changes) were performed in 
51% of the subtherapeutic, 33% of the therapeutic, and 
24% of patients of the supratherapeutic TL groups (p = 
0.04).
When subdividing the reasons for TL measurements 
(Fig. 1) into the subsequent TL results, it became apparent 
that of the 65 patients (out of 104 in total) presenting with 
a clinical surrogate for increased disease activity (clinical 
flare, a sonographic or endoscopic activity, or elevated 
laboratory parameters), only 19 patients (29%) actually 
had subtherapeutic TL (Table 3). Twenty-five (38%) and 
21 (32%) patients had therapeutic and supratherapeutic 
TLs, respectively (p = 0.16). This analysis shows that in 
our patient collective, there is no evidence for a correla-
tion between disease activity and TL results.
Therapeutic Consequences of ADA Measurements
ADA levels were determined in all 104 patients. Pres-
ence of ADA according to TL subgroups is presented in 
Table 4. Sixteen patients (14%) had positive ADA titers, 
and as expected, 15 of them presented with subtherapeutic 
TL results. Thirteen of the 64 patients treated with inflix-
imab (20%) and 3 of the 40 patients treated with adalim-
umab (8%) developed ADA. Therapeutic consequences of 
ADA presence are illustrated in Figure 3. The presence of 
ADA motivated to a switch in treatment in the majority of 
patients (n = 6). Moreover, to suppress the occurrence of 
increase of ADA, 4 patients received the addition of an 
immunomodulatory treatment with AZA or MTX. ADA 
disappeared in 2 patients treated with MTX. Another pa-
tient received MTX but was later switched to golimumab, 
after the cost approval from the insurance was received. 
The addition of AZA was not successful in 1 patient and 
was switched from infliximab to adalimumab.
Table 2. Adaptation of anti-TNF therapy following TL 
measurements: treatment changes regarding anti-TNF therapy 
(i.e., alteration of treatment interval, dosing, stopping or switching 
to another biological therapy) were only significant in patients 




no (n) yes (n)
TL
Subtherapeutic 9 24 0.01
Therapeutic 22 11 0.08
Supratherapeutic 23 15 0.26





■ Switch of biological treatment
■ Anti-TNF therapy stop
■ Additional immunomodulator
■ Interval shortening
Fig. 3. Presence of ADAs and therapeutic consequences. Switch in 
biological treatment (n = 6) to infliximab, adalimumab, certolizu-
mab pegol, or golimumab. Stopping anti-TNF therapy (n = 5; due 
to quiescent disease [n = 3] and preparation for surgery [n = 2]). 
Additional immunomodulatory treatment (n = 4): AZA and MTX. 
Interval shortening (n = 1). ADAs, anti-drug antibodies; TNF, tu-
mor necrosis factor; AZA, azathioprine; MTX, methotrexate.
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ADAs and Their Association with Infusion Reactions
ADA may be related to adverse infusion reactions [21–
24]. Thirteen of the 104 patients presented with suspected 
infusion reactions, such as a sudden asthma crisis, ery-
thema, or pruritus during or immediately after treatment 
with infliximab. ADAs were found in 7 patients with in-
fusion reactions. Thus, the odds ratio for the develop-
ment of an infusion reaction in the presence of ADA was 
10.6 (95% CI 2.9–38.6, risk ratio of 5.4) compared to de-
veloping an infusion reaction without the presence of 
ADA. One patient had a confirmed anti-TNF therapy-
induced lupus-like syndrome without the presence of 
ADA.
ADA development in patients initially not presenting 
any ADA was observed in 2 patients (treated with adali-
mumab) during the study period. Addition of mercapto-
purine or MTX could not reverse ADA, and therefore, 
treatment was changed to ustekinumab.
Reasons for Treatment Adjustments
Treatment adaptions were performed in 63 out of the 
104 patients (Fig. 2). As expected, most treatment adapta-
tions were performed in the group with subtherapeutic 
TL. However, since treatment adaptions performed by 
the treating physician did not frequently correlate with 
clinical surrogates of disease activity (see above), we ana-
lyzed the specific reasons for the executed treatment ad-
aptations based on our patients’ health records. We inves-
tigated whether treatment adaptations were carried out 
primarily due to TL and/or ADA results or, in contrast, 
were based on findings obtained from other investiga-
tions, for example, clinical symptoms, sonography, en-
doscopy, or laboratory results (Table 5).
Table 4. Presence of ADAs and corresponding TLs
Presence of ADAs Total p value
no yes
TL
Subtherapeutic 18 15 33 <0.01
Therapeutic 33 0 33 <0.01
Supratherapeutic 37 1 38 <0.01
Total 88 16 104
ADAs, anti-drug antibodies; TL, trough level.
Table 5. Reasons for treatment adaptations as documented by 
physicians’ records
Treatment adaptations  




TL (n = 63)
Subtherapeutic 9 21 0.05
Therapeutic 9 6 0.61
Supratherapeutic 9 9 1.0
Total 27 36 0.31
No: Treatment adaptations were based on clinical, sonograph-
ic or endoscopic activity, or laboratory values. Yes: Treatment ad-
aptations were based on results of TL or ADAs. Only patients with 
anti-TNF therapy and other treatment adaptations were included. 
Data of the 41 patients without any treatment adaptations are not 
shown. TL, trough level; ADAs, anti-drug antibodies; TNF, tumor 
necrosis factor.
Table 3. Reasons for TL measurements subdivided into corresponding TL results: Surrogates for disease activity 
(clinical flare, sonographic or endoscopic activity, and elevated laboratory parameters) did not correlate with 
trough level results (p = 0.16)
TL Total
subtherapeutic (n) therapeutic (n) supratherapeutic (n)
Reasons for TL measurement
Clinical flare 10 15 13 38
Sonographic activity 4 4 2 10
Endoscopic activity 3 1 2 6
Elevated laboratory parameters 2 5 4 11
Total 19 25 21 65
TL, trough level.
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In the subtherapeutic TL group, 15 patients had posi-
tive ADA titers. In this group, the decision for treatment 
adjustment was led by TL and/or ADA results in 70%. In 
the therapeutic TL group, no patient had ADA. In this 
group, the decision for treatment adjustment in order to 
achieve endoscopic remission was guided by TL results in 
40%, while in 60%, other reasons were more important 
for treatment adaptations.
In the supratherapeutic TL group, treatment was al-
tered in 50% due to TL results, such that the infusion in-
tervals were extended or treatment was stopped. In the 
remaining 50%, increased disease activity (based on clin-
ical symptoms, sonography, endoscopy, or laboratory re-
sults) resulted in an intensification of anti-TNF therapy.
Repetition of TL Measurements: Time Interval and 
Disease Activity Scores
In our patient collective, the average time interval be-
tween start of anti-TNF therapy and first TDM measure-
ment was 150 days (minimum: 13 days, maximum: 700 
days, SD: 148 days, IQR: 120 days). In 54 out of 104 (52%) 
patients, the measurement of TL and ADA was repeated 
after treatment adjustments. The remaining 50 patients 
did not have any TDM follow-up due to quiescent dis-
ease, treatment changes to medications other than anti-
TNF therapy, or a complete treatment stop.
During the treatment interval, clinical scores did not 
change. At the time of follow-up, CD patients (n = 31) had 
a mean HBI of 5.58 (IQR: 5) versus 5.68 (IQR: 5) at the 
initial measurement (p = 0.88). UC patients (n = 15) had 
a mean MTWSI of 5.27 (IQR: 7) versus 6.87 (IQR: 6) (p = 
0.13). By the end of the observation period, 94.7% (36 out 
of 38 patients) of patients presenting with supratherapeu-
tic TL remained on the same anti-TNF therapy, 93.9% (31 
out of 33 patients) in the therapeutic TL group, and 54.5% 
(18 out of 33 patients) in the subtherapeutic TL group.
Discussion
Strict guidelines for the measurement of TL and ADA in 
IBD patients treated with anti-TNF antibodies are missing. 
Accordingly, TDM might be done unnecessarily or without 
drawing the correct conclusions. In our present study, we 
retrospectively analyzed the reasons for and consequences 
of TL and ADA measurements in clinical routine in a large 
tertiary Swiss IBD center under real-world conditions. As 
expected, subtherapeutic TL frequently led to a treatment 
intensification. However, there was no correlation between 
TL and disease activity, and even supratherapeutic TLs 
were followed by treatment intensification – therefore be-
ing overruled by clinical presentation of the patient. Of 
note, we also found that presence of ADA significantly in-
creased the likelihood for an infusion reaction following 
anti-TNF antibody administration.
TL might depend on individual variations in pharma-
cokinetics and pharmacodynamics in each patient [25–
27]. Therefore, it is still unknown if the measurement of 
TL, rather than peak or intermediate drug levels, is repre-
senting an adequate surrogate marker for drug concen-
trations [16]. Additionally, TL may be influenced by sex, 
serum albumin concentration, and disease activity [28–
30]. Furthermore, non-TNF-related inflammatory path-
ways have to be considered with respect to the underlying 
cause of disease activity [31].
In our patient collective, positive ADA titers correlated 
with subtherapeutic TL in 15 out of 16 patients, reflecting 
the known drug-neutralizing effect of ADA [4, 32]. The 
remaining patient with positive ADA had supratherapeu-
tic TL and could represent a phenomenon of transient 
ADA development without any clinical impact [11, 33]. 
The observed development of acute infusion reactions in 
44% of ADA-positive patients corresponds with results 
found in other studies [34, 35]. Change of anti-TNF ther-
apy in the presence of ADA – as performed in the major-
ity of our patient collective – is supported by other results 
and guidelines, which, however, demonstrated that in the 
presence of ADA dose increase alone leads to a therapeu-
tic response in only a minority of patients [9, 15]. In con-
trast, if no ADAs are present, therapy intensification can 
reinstate therapeutic response [15, 16].
In our clinic, the decision of treatment adjustments was 
primarily led by TL and ADA results (rather than by other 
investigations) only in the group of patients with subther-
apeutic TL. These results have to be interpreted with cau-
tion, as modifications in this group were associated with 
the presence of ADA in 15 out of 33 patients. Subtherapeu-
tic TLs mainly result from the drug-neutralizing effects of 
ADA in patients treated with infliximab and adalimumab, 
rather than from insufficient therapy administration [4, 
24, 32, 36]. Future studies should address if solely the pres-
ence of ADA – without the measurement of correspond-
ing TL – leads to significant treatment adaptations, as the 
results of therapeutic and supratherapeutic TLs in our pa-
tient collective had no significant consequences on treat-
ment adaptation. In addition, a previous study demon-
strated that a longer duration of subtherapeutic TL corre-
lated with reduced ADA development [37].
Treatment intensification in case of supratherapeutic 
TL and ongoing disease activity in our patient collective 
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was mainly performed to achieve endoscopic remission. 
This is in accordance with findings of other studies [38, 
39]. For supratherapeutic TL, explicit guidelines for ther-
apy adaptation are lacking. This is partially due to the fact 
that until now no clear association between high or supra-
therapeutic TL and toxicity or specific adverse effects has 
been described [40]. Initially, high anti-TNF therapy con-
centrations have been associated with arthralgia and skin 
lesions as a result of a “paradoxical inflammation” [41]. 
This association has not been confirmed in follow-up 
studies [42, 43]. Additionally, it was recently demonstrat-
ed that there is no association between more frequent in-
fections and supratherapeutic infliximab TL [44]. Our re-
sults indicate that in case of a quiescent disease and su-
pratherapeutic drug levels, treatment intervals might be 
prolonged, as these adaptations have a direct impact on 
cost-effective medicine. However, this needs to be vali-
dated in prospective studies.
A limitation of our study is its retrospective nature as 
well as a potential bias in the selection of patients: by omit-
ting any exclusion criteria, we created a heterogeneous IBD 
patient group, especially by summarizing CD and UC pa-
tients. This is, however, also one of the strengths of our 
study, since we present the real-world data and not data 
from a highly selected clinical trial population. Notably, 
CD and UC patient groups showed no significant differ-
ences regarding age, sex, or treatment regimen (adalim-
umab or infliximab). Additionally, by exclusively includ-
ing patients referred to an IBD specialized tertiary clinic, 
we mainly selected a patient collective with a severe disease 
course. This fact is represented by the high number of UC 
patients presenting with pancolitis (E3: 43%) and a high 
proportion of CD patients exhibiting a penetrating disease 
course (B3: 54%). This might, however, also mirror a cer-
tain diligence of the treating physician in severely diseased 
colitis patients, who especially in those patients use the 
possibility of TDM. Thus, proactive TDM was mostly ob-
served in clinicians less experienced in IBD treatment.
In conclusion, our study shows that TL and ADA are 
primarily used to confirm treatment decisions according 
to clinical disease activity. This supports a reactive rather 
than a proactive drug monitoring strategy. Moreover, as 
TLs do not correlate with disease activity, it remains dif-
ficult to establish clear guidelines for drug monitoring in 
clinical routine. On the other hand, proactive TDM could 
be performed in patients in remission, where suprathera-
peutic TL could justify a therapy de-escalation to save 
treatment costs.
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